Please enable JavaScript or talk to your local administrator to get JavaScript enabled.
Skip filters
Skip facets
Funder
  • 173

  • 98

  • 23

  • 22

  • 20

  • 19

  • 17

  • 16

  • 13

  • 11

Funder Group
Research Organization
FOR (ANZSRC) Category
RCDC Category
Researcher
City
State
Country
Country of Funder
Start Year
Active Year
Similar Projects for

Project

CATIONIC COMPOUNDS FOR THERAPY OF BLADDER CANCER

Funder: National Cancer Institute

Funding period
0
Funding amount
Abstract
Carcinoma of the bladder is a multifocal disease which recurs in approximately 70% of patients. Treatment with conventional chemotherapy administered either systemically or intravesically has a disadvantage of causing adverse effects for normal, as well as, malignant cells. Recently, studies with cationic rhodamine dyes have revealed that malignant transitional cells absorb this dye and bind it to the mitochondria for prolonged periods of time. This has the effect of interferring with cell growth and causes a preferential toxicity to the cancer cells. Previous investigators have demonstrated that intraperitoneal administration of a rhodamine compound to animals with an intrapertineal bladder tumor can prolong survival. We propose to use an intravesical bladder tumor model in mice to assess whether these compounds are still active against a tumor growing in the bladder. These studies are important because of the therapeutic and diagnostic implications for patients with this disease. This tumor model is ideal because it closely mimics the human situation. The long-term objective is to determine whether rhodamine dyes will be useful for treating human transitional cell carcinoma by either the systemic or intravesical route. In addition, the ability of these and other cationic compounds to localize malignant areas of the bladder will be determined first in an experimental model and then in humans. The work will promarily use an intravesical transitional cell tumor model which results in reproducible tumor growth and in relatively constant median survival. In vivo binding and histological changes will be determined following intraperitoneal and intraversical drug administration. Various cationic compounds will be tested in vitro and in vivo to determine which drug has maximum activity against this tumor. The optimum schedule of drug administration will be assessed by varying the time, dose, duration, frequency and location of drug administration. Comparisons of various cationic compounds will be made by quantitative correlations of chemical localization in tumor and normal urothelium by histochemistry and mitochondrial subcellular fractionation with biochemical alterations in mitochondrial oxidative phosphorylation and with tumor growth and host survival. Following the experimental studies, a pilot study is planned in humans to determine if intravesical administration of rhodamine or other cationic compounds can assist in the localization and therapy of intravesical bladder tumors.

 
519
Projects
USD 203.0 M
Aggregated funding amount
USD 549 K
Average funding amount
Project list item
Intravesical delivery of an Fc-enhanced CD40 agonist antibody for the treatment of bladder cancer

Bladder Cancer Advocacy Network to Jeffrey Ravetch, David Knorr

USD 300,000
2020 - 2022
Project list item
Epigenetic regulators of subtype plasticity in bladder cancer

Bladder Cancer Advocacy Network to John Robert Christin

USD 1,700
2020 - 2020
Project list item
Characterization of Nectin-4 expression in molecular subtypes of urothelial cancer and mechanisms of resistance to enfortumab vedotin

Bladder Cancer Advocacy Network to Carissa Ellen Chu

USD 1,700
2020 - 2020
Project list item
Recombinant CCL2 as a novel treatment strategy for bladder cancer

Bladder Cancer Advocacy Network to Neelam Mukherjee, Robert Scott Svatek

USD 50,000
2020 - 2021
Project list item
Defining NRF2 induced tumor invasion in bladder cancer

Bladder Cancer Advocacy Network to Yuki Kita, William Youngkwan Kim, Bernard Weissman

USD 50,000
2020 - 2021
Project list item
Targeting regulatory B cells (Bregs) to improve anti-bladder cancer immunity

Bladder Cancer Advocacy Network to Burles Avner Johnson, David McConkey

USD 50,000
2020 - 2021
Project list item
Alpha1H: A Unique Bladder Cancer Therapeutic, Acting with Great Precision

European Commission

USD 2,452,885
2020 - 2022
Project list item
Implication of neutrophil extracellular traps in the efficacy of bladder-sparing therapy in muscle invasive bladder cancer

Canadian Institutes of Health Research to Wassim Kassouf, Ciriaco A. Piccirillo, Jonathan David Spicer

USD 138,878
2020 - 2025
Project list item
CD40 agonism for the treatment of bladder cancer

National Cancer Institute to CHRISTOPHER STUART GARRIS

USD 64,554
2020 - 2023
Project list item
A new bladder cancer model based on tissue reprogramming and gene targeting

National Cancer Institute to FLAMINIA TALOS, DAIFENG WANG

USD 203,843
2020 - 2021
Project list item
Roles of epigenetic regulators in bladder cancer progression

University of California - Cancer Research Coordinating Committee to Zhu Wang

USD 74,960
2020 - 2020
Project list item
Unravelling Mechanisms of Resistance to Checkpoint Inhibition in Canine Urothelial Carcinoma

V Foundation for Cancer Research to Nicola J. Mason

USD 500,000
2019 - 2021
Project list item
Engineering Smart Solutions for Disorders of the Bladder Urothelium

Engineering and Physical Sciences Research Council

 
2019 - 2023
Project list item
Bladder cancer chemotherapy potentiation with a multiprong arachidonic acid pathway modulator

National Cancer Institute to PAUL THOMAS HENDERSON

USD 300,000
2019 - 2020
Project list item
[The association between SORL1 and advanced bladder cancer] - Original in Japanese

Japan Society for the Promotion of Science to Takanobu UTSUMI

USD 26,335
2019 - 2021
Project list item
Developing a SMART scaffold for bladder augmentation

National Institute of Biomedical Imaging and Bioengineering to GUILLERMO ANTONIO AMEER, JOHN ROGERS, ARUN SHARMA

USD 1,399,891
2019 - 2023
Project list item
Transdifferentiation of fibroblasts to urothelial progenitors for definitive urothelial replacement therapy in non-muscle invasive bladder cancer

Bladder Cancer Advocacy Network to Philip A Beachy, Kris Butalid Prado

USD 300,000
2019 - 2021
Project list item
Refined phenotyping and personalized targeting of muscle-invasive bladder cancer

Swiss National Science Foundation to Roland Seiler, Vera Genitsch, Marianna Kruithof-de Julio, Federico La Manna, Martina Minoli, Kiu Yan Charlotte Ng, Franziska Singer, Eugenio Zoni

USD 709,398
2019 - 2023
load more...